A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSCG Cell Therapy Pte. Ltd.
About this trial
This Phase 1/ 2a study is a multicenter study to evaluate the safety, tolerability and efficacy of SCG101 in subjects with hepatitis B virus-related hepatocellular carcinoma
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)
Subjects with HCC who have received at least 2 standard systemic therapies
HLA-A *02
BCLC stage B or C
Disqualifiers
Subjects with history of another primary cancer
Untreated or active central nervous system (CNS) or leptomeningeal metastasis, or history of hepatic encephalopathy, or other clinically significant CNS diseases
Autoimmune diseases requiring immunosuppressive therapy (except topical medication) or subjects with significant persistent immune rejection
Known history of neurological or mental disorder, including epilepsy or dementia
Trial design
Treatments tested in this trial
- SCG101
Treatment groups
46 Participants
are divided into 1 treatment groupLocations
6Hong Kong
Hong Kong is. Hong Kong Hong Kong
Hong Kong NT Hong Kong Hong Kong
Singapore
Singapore169610, Singapore Singapore
Singapore228510, Singapore Singapore
Sponsors and collaborators
SCG Cell Therapy Pte. Ltd.
Lead sponsor
Source ClinicalTrials.gov